Combination cardiometabolic therapy in type 2 diabetes: optimizing SGLT2 inhibitor and GLP‑1 receptor agonist use.
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
publication date
- July 18, 2026
published in
- Current atherosclerosis reports Journal